<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2010">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03080714</url>
  </required_header>
  <id_info>
    <org_study_id>Triton AP</org_study_id>
    <nct_id>NCT03080714</nct_id>
  </id_info>
  <brief_title>Triton Agreement and Precision Study</brief_title>
  <official_title>Topcon DRI OCT Triton Agreement and Precision Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Topcon Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Topcon Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To Compare the agreement and precision between the Topcon DRI OCT Triton and the 3D OCT-1
      Maestro with RDB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of this study are to compare the agreement and precision between Topcon DRI
      OCT Triton and 3D OCT-1 Maestro with RDB by measuring the thickness layers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2017</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal Thickness</measure>
    <time_frame>1 Minute</time_frame>
    <description>The thickness of the macula layer</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Healthy Eyes</condition>
  <condition>Eye Diseases</condition>
  <arm_group>
    <arm_group_label>Subjects Presenting With Normal Eyes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with no known ocular diseases will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects presenting with Retinal Disease</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with Retinal diseases will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects presenting with Glaucoma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects with Glaucoma will be scanned on the Topcon DRI OCT Triton (plus) device and 3D OCT-1 Maestro</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Topcon DRI OCT Triton (plus)</intervention_name>
    <description>The Topcon DRI OCT Triton (plus) is an OCT machine used for diagnostic purposes</description>
    <arm_group_label>Subjects Presenting With Normal Eyes</arm_group_label>
    <arm_group_label>Subjects presenting with Retinal Disease</arm_group_label>
    <arm_group_label>Subjects presenting with Glaucoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3D OCT-1 Maestro</intervention_name>
    <description>The 3D OCT-1 Maestro is an OCT machine used for diagnostic purposes</description>
    <arm_group_label>Subjects Presenting With Normal Eyes</arm_group_label>
    <arm_group_label>Subjects presenting with Retinal Disease</arm_group_label>
    <arm_group_label>Subjects presenting with Glaucoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Normal Group

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to participate
             as evidenced by signing the informed consent

          3. Subjects presenting at the site with normal eyes bilaterally (cataracts are
             acceptable)

          4. IOP ≤ 21 mmHg bilaterally

          5. BCVA 20/40 or better bilaterally

        Exclusion Criteria for Normal Group

          1. Subjects unable to tolerate ophthalmic imaging

          2. Subjects with ocular media not sufficiently clear to obtain acceptable OCT images

          3. HFA visual field (24-2 Sita Standard, white on white) result unreliable (based on
             manufacturer's recommendation), defined as fixation losses &gt; 20% or false positives &gt;
             33%, or false negatives &gt; 33%

          4. Visual field defects consistent with glaucomatous optic nerve damage based on at
             least one of the following two findings:

               1. On pattern deviation (PD), there exists a cluster of 3 or more points in an
                  expected location of the visual field depressed below the 5% level, at least 1
                  of which is depressed below the 1% level;

               2. Glaucoma hemi-field test &quot;outside normal limits.&quot;

          5. Narrow angle

          6. History of leukemia, dementia or multiple sclerosis

          7. Concomitant use of hydroxychloroquine and chloroquine

        Inclusion Criteria for Glaucoma Group

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to participate
             as evidenced by signing the informed consent

          3. BCVA 20/40 or better in the study eye

          4. Visual field defects consistent with glaucomatous optic nerve damage based on at
             least one of the following two findings:

               1. On pattern deviation (PD), there exists a cluster of 3 or more points in an
                  expected location of the visual field depressed below the 5% level, at least 1
                  of which is depressed below the 1% level;

               2. Glaucoma hemi-field test &quot;outside normal limits.&quot;

          5. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or
             retinal nerve fiber layer structural abnormalities:

               1. Diffuse thinning, focal narrowing, or notching of the optic disc rim, especially
                  at the inferior or superior poles with or without disc hemorrhage;

               2. Localized abnormalities of the peripapillary retinal nerve fiber layer,
                  especially at the inferior or superior poles; or

               3. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural
                  tissue

        Exclusion Criteria for Glaucoma Group

          1. Subjects unable to tolerate ophthalmic imaging

          2. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

          3. HFA visual field (24-2 Sita Standard, white on white) result unreliable, defined as
             fixation losses &gt; 20% or false positives &gt; 33%, or false negatives &gt; 33% in the study
             eye

          4. Presence of any ocular pathology except glaucoma in the study eye (cataracts are
             acceptable)

          5. History of leukemia, dementia or multiple sclerosis

          6. Concomitant use of hydroxychloroquine and chloroquine

        Inclusion Criteria for Retina Disease Group

          1. Subjects 18 years of age or older on the date of informed consent

          2. Subjects able to understand the written informed consent and willing to participate
             as evidenced by signing the informed consent

          3. Subjects presenting at the site with retinal disease

          4. IOP ≤ 21 mmHg in the study eye

          5. BCVA 20/400 or better in the study eye

          6. Diagnosis of some type of retinal pathology by investigator, may include, but not
             limited to: Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy,
             Macular Hole, Epiretinal Membrane, Cystoid Macula Edema, and others

        Exclusion Criteria for Retinal Disease Group

          1. Subjects unable to tolerate ophthalmic imaging

          2. Subject with ocular media not sufficiently clear to obtain acceptable OCT images

          3. Presence of glaucoma or any ocular pathology other than a Retinal pathology (e.g.,
             cornea pathology) in the study eye (cataracts are acceptable)

          4. Narrow angle in the study eye

          5. History of leukemia, dementia or multiple sclerosis

          6. Concomitant use of hydroxychloroquine and chloroquine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Riesman, MS</last_name>
    <role>Study Chair</role>
    <affiliation>Topcon Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Danny Leung, BS</last_name>
    <phone>(925)245-7734</phone>
    <email>dleung@topcon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fischer Laser Eye Center</name>
      <address>
        <city>Willmar</city>
        <state>Minnesota</state>
        <zip>56201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Boehme</last_name>
      <phone>320-214-5771</phone>
      <email>peggyb@fischerlaser.com</email>
    </contact>
    <investigator>
      <last_name>Jefferey Fischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 30, 2017</lastchanged_date>
  <firstreceived_date>March 7, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>no known ocular pathology</keyword>
  <keyword>Glaucoma</keyword>
  <keyword>Retinal Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
